295350-45-7

295350-45-7 structure

Name: H-Pro-Gly-NH2 · HCl
Chemical Name: Ozarelix
CAS Number: 295350-45-7
Molecular Formula: C₇₂H₉₆ClN₁₇O₁₄
Molecular Weight: 1459.091
Catalog: Signaling Pathways Apoptosis Apoptosis
Create Date: 2018-05-23 08:00:00
Modify Date: 2024-01-09 14:37:00
Ozarelix (D-63153) is a GnRH antagonist. Ozarelix induces cell apoptosis and arrests cell in G2/M phase. Ozarelix can be used in the research of prostate cancer[1].

Name	Ozarelix
Synonyms	Ozarelix N-Acetyl-3-(2-naphthalenyl)-D-alanyl-4-chloro-D-phenylalanyl-3-(3-pyridinyl)-D-alanyl-L-seryl-N-methyl-L-tyrosyl-N6-(aminocarbonyl)-D-lysyl-L-norleucyl-L-arginyl-L-prolyl-D-alaninamide D 63153 D-Alaninamide, N-acetyl-3-(2-naphthalenyl)-D-alanyl-4-chloro-D-phenylalanyl-3-(3-pyridinyl)-D-alanyl-L-seryl-N-methyl-L-tyrosyl-N-(aminocarbonyl)-D-lysyl-L-norleucyl-L-arginyl-L-prolyl- D-63153 N-Acetyl-3-(2-naphthyl)-D-alanyl-4-chloro-D-phenylalanyl-3-(3-pyridinyl)-D-alanyl-L-seryl-N-methyl-L-tyrosyl-N-carbamoyl-D-lysyl-L-norleucyl-L-arginyl-L-prolyl-D-alaninamide UNII-Q1IF8M2YL3

Description	Ozarelix (D-63153) is a GnRH antagonist. Ozarelix induces cell apoptosis and arrests cell in G2/M phase. Ozarelix can be used in the research of prostate cancer[1].
Related Catalog	Signaling Pathways >> GPCR/G Protein >> GNRH Receptor Signaling Pathways >> Apoptosis >> Apoptosis Research Areas >> Cancer
In Vitro	Ozarelix (0-20 ng/mL, 72 h) inhibits PC3 and DU145 cell proliferation[1]. Ozarelix (0-20 ng/mL, 72 h) induces apoptosis in PC3 and DU145 cells[1]. Ozarelix (20 ng/mL, 72 h) triggers caspase 8-dependent caspase 3 activation[1]. Cell Proliferation Assay[1] Cell Line: Serum-starved PC3 and DU145 cells Concentration: 0, 5, 10, 20 ng/mL Incubation Time: 0, 24, 48, 72, 96 h Result: Inhibited cell proliferation in a dose and time-dependent manner. Western Blot Analysis[1] Cell Line: PC3 and DU145 cells Concentration: 0, 5, 10, 20 ng/mL Incubation Time: 72 h Result: Increased the levels of p21 and p27 both in PC3 and DU145 cells. Decreased levels of anti-apoptotic proteins such as Bcl2 and Bcl-Xl. Upregulated Erk and p38MAPK activity.